ArchiMed, an investment firm focused exclusively on the healthcare industry, completed the investment in Corealis Pharma, a private company that partners with the pharmaceutical and biotechnology industries. Financial terms were not disclosed. “ArchiMed understood our strategy and offered an attractive investment thesis. We turned down several higher offers from prospective suitors - trade and financial. Like us, ArchiMed understands the important potential of this industry and what it takes to get to the next level. As partners we’ll be able to capitalize on market leadership, aggressively expanding scientific strengths in R&D and our best-in-class regulatory-compliant manufacturing processes [such regulatory compliant processes are known as Good Manufacturing Practices or GMP]," Yves Roy, Corealis President.